Login / Signup

Analysis of the US Safety Data for Edaravone (Radicava ® ) From the Third Year After Launch.

Angela GengeBenjamin Rix BrooksBjörn OskarssonAlexander KalinMing JiStephen AppleLaura Bower
Published in: Drugs in R&D (2022)
In the postmarketing reporting to date, no new safety signals were identified beyond those already known from the edaravone clinical trial program.
Keyphrases
  • clinical trial
  • electronic health record
  • quality improvement
  • big data
  • adverse drug
  • randomized controlled trial
  • emergency department
  • study protocol
  • machine learning
  • artificial intelligence
  • data analysis